News of Note—Themis’ Chikungunya vaccine, Gardasil protests and more


Here is some other vaccine news of note for the week.

> The European Medicines Agency has granted Themis’ phase 2 chikungunya vaccine candidate Priority Medicines (PRIME) designation, which is designed to provide enhanced regulatory support. Release

> A group of women protested at Merck’s office in Hong Kong to express their unhappiness over a shortage of Gardasil 9 in the area and to urge the firm to increase the supply. South China Morning Post article

> Healthcare mogul Patrick Soon-Shiong plans to take public a cancer vaccine biotech later this year to finance the development of six candidates currently in clinical trials against nine tumor types. FierceBiotech article

> The FDA granted a priority review for Merck's Gardasil 9 in women and men ages 27 to 45 with a PDUFA date of Oct. 6, 2018. Release

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

Pfizer's shot will go before an FDA expert panel on Dec. 10, with Moderna's review pegged for the 17th, Warp Speed chief Moncef Slaoui, Ph.D., said.